Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.450
-0.070 (-1.99%)
Nov 13, 2026, 4:00 PM EST - Market closed
Prelude Therapeutics Revenue
Prelude Therapeutics had revenue of $5.70M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $22.42M, up 220.34% year-over-year. In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth. That makes Prelude Therapeutics the 33,162nd largest company in the world by revenue and 4,346th in the United States.
Revenue (ttm)
$22.42M
Revenue Growth
+220.34%
P/S Ratio
15.85
Revenue / Employee
$283,848
Employees
79
Market Cap
355.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.14M | 5.14M | 73.43% |
| Dec 31, 2024 | 7.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alector | 173.47M |
| Editas Medicine | 49.83M |
| C4 Therapeutics | 32.28M |
| Evommune | 10.00M |
| YD Bio | 1.24M |
| ProKidney | 775.00K |
| Lyell Immunopharma | 15.00K |
PRLD News
- 25 days ago - Prelude Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 4 weeks ago - Prelude Therapeutics to Participate in the Chardan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - H.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly - TheFly
- 4 weeks ago - Prelude enters clinical trial collaboration, supply agreement with Eli Lilly - TheFly
- 4 weeks ago - Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer - GlobeNewsWire
- 1 month ago - Prelude Therapeutics initiated with an Overweight at JPMorgan - TheFly
- 1 month ago - Prelude Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire